TWi Pharmaceuticals, Inc. today confirmed that the United States District Court for the Northern District of California has found two claims of United States Patent No. 7,737,282 (the '282 Patent) valid and infringed by TWi' generic version of Takeda's Dexilant® (Dexlansopraozle delayed-release capsules). Takeda initiated the suit against TWi on six patents (United States Patent No. 6,462,058, 6,664,276; 6,939,971; 7,285,668; 7,790,755; 7,737,282 ) in 2011. TWi had previously prevailed on the other five patents. TWi respectfully disagrees with the Court's decision on the ‘282 patent and intends to appeal the decision.

According to IMS Health, a market research firm, the total annual sales of Dexilant○R in U.S. were approximately $771 million in 2012.

About TWi Pharmaceuticals, Inc.

TWi Pharmaceuticals, Inc. is a leading specialty pharmaceutical company based in Taipei, Taiwan, focusing on the development of high barrier generic prescription products ranging from oral controlled release dosage form to novel drug delivery systems including the utilization of nanoparticles, transdermal, and polymeric oral delivery systems. Leveraging its internal research and development capabilities, together with operational flexibility, process development, manufacturing and regulatory expertise, TWi Pharmaceuticals concentrates on products and technologies that present significant barriers to entry or offer Paragraph IV first-to-file or first-to-market opportunities in the United States. For more information of TWi Pharmaceuticals, please visit www.twipharma.com.

Contact:
Liru Yeh
Head of Investor Relations
Tel: +886-2-2657-3350
email: liru.yeh@twipharma.com